SequelSEC

ROCKET PHARMACEUTICALS, INC. RCKT

Pharmaceutical Preparations · CIK 0001281895 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$46.92M
Fiscal year ended 2026-06-30
Free cash flow
-$39.62M
Fiscal year ended 2026-06-30

ROCKET PHARMACEUTICALS, INC. (RCKT) reported revenue of $0 and net income of $123.21M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ROCKET PHARMACEUTICALS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ROCKET PHARMACEUTICALS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$0$0$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$46.92M-$48.51M-$43.96M-$52.25M-$71.15M-$64.39M-$62.69M-$69.42M-$73.71M-$67.38M
Net income$123.21M-$47.59M-$42.54M-$50.33M-$68.92M-$61.33M-$60.33M-$66.72M-$69.65M-$62.05M
Research & development$29.50M$31.45M$29.35M$34.07M$42.66M$35.94M$37.36M$42.32M$46.34M$45.23M
Weighted-average diluted sharesshares 114.51Mshares 112.13MUnavailableshares 111.57Mshares 111.02Mshares 110.09MUnavailableshares 94.16Mshares 93.75Mshares 93.55M
Pretax income$131.84MUnavailableUnavailableUnavailable-$68.92MUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$8.62MUnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$1.08$-0.42Unavailable$-0.45$-0.62$-0.56Unavailable$-0.71$-0.74$-0.66
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$17.42M$17.06M$14.68M$18.35M$25.02M$28.45M$25.34M$27.11M$27.37M$22.15M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ROCKET PHARMACEUTICALS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$224.51M$49.61M$77.56M$75.95M$32.82M$49.81M$163.64M$65.60M$38.61M$35.28M
Total assets$423.10M$285.41M$330.45M$368.03M$420.98M$471.07M$527.70M$393.69M$446.41M$499.44M
Current assets$289.55M$149.83M$192.73M$227.68M$277.16M$324.49M$378.18M$241.75M$292.72M$345.16M
Total liabilities$54.27M$47.37M$53.23M$54.36M$66.77M$58.93M$64.47M$63.92M$61.78M$57.94M
Current liabilities$31.32M$24.47M$30.21M$31.17M$43.40M$35.31M$40.68M$39.98M$37.59M$32.96M
Total equity incl. NCI$368.83M$238.04M$277.22M$313.67M$354.21M$412.14M$463.23M$329.77M$384.64M$441.50M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$39.15M$39.15M$39.15M$39.15M$39.15M$39.15M$39.15M$39.15M$39.15M$39.15M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

ROCKET PHARMACEUTICALS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$39.61M-$45.39M-$34.84M-$50.42M-$48.96M-$55.79M-$46.94M-$52.10M-$53.82M-$56.86M
Capital expenditures$8.00K$93.00K$80.00K-$54.00K$50.00K$364.00K$309.00K$1.59M$1.93M$2.04M
Investing cash flow$214.36M$17.45M$36.42M$93.62M$31.76M-$58.04M-$37.87M$78.92M$55.62M$35.03M
Financing cash flow$150.00K-$1.00K$0-$67.00K$215.00K$0$182.85M$176.00K$1.53M$1.18M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$7.42M$8.49M$6.11M$9.76M$10.86M$10.33M$11.09M$11.25M$11.33M$10.25M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.60M$1.60M$1.70M$2.70M$2.00M$2.50M$1.80M$1.90M$1.80M$1.70M

Derived

ROCKET PHARMACEUTICALS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$39.62M-$45.49M-$34.92MUnavailable-$49.01M-$56.15M-$47.25M-$53.69M-$55.75M-$58.89M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio9.24x6.12x6.38x7.30x6.39x9.19x9.30x6.05x7.79x10.47x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate6.5%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RCKT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.